Announced details
Treatment of recurrent glioblastoma
In the Phase Ia trial, disease stability was maintained for 312 days in 1 patient, and a partial response was confirmed during that period.
1 patient in the Phase Ia trial. Whether this is cumulative or as of a specific date is not disclosed.
The drug product being developed by NANO MRNA Co., Ltd. is based on the research results of Nagoya University Graduate School of Medicine. Capital, personnel and business relationships are not disclosed.
Nagoya University Graduate School of Medicine. TUG1 ASO was developed based on the research results of Yutaka Kondo (近藤豊), Professor of Tumor Biology, and Ryuta Saito (斎藤竜太), Professor of Neurosurgery, is the clinical trial principal investigator. Other information on location, capital and year of establishment is not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | TUG1 ASO |
| Counterparty | Nagoya University Graduate School of Medicine (affiliation of the research results and the clinical trial principal investigator) |
| Counterparty overview | Nagoya University Graduate School of Medicine. TUG1 ASO was developed based on the research results of Yutaka Kondo (近藤豊), Professor of Tumor Biology, and Ryuta Saito (斎藤竜太), Professor of Neurosurgery, is the clinical trial principal investigator. Other information on location, capital and year of establishment is not disclosed. |
| Relationship with the Company | The drug product being developed by NANO MRNA Co., Ltd. is based on the research results of Nagoya University Graduate School of Medicine. Capital, personnel and business relationships are not disclosed. |
| Launch date | 31 August 2026 (actual; the trial and dosing of the first patient began) |
| Applicable area | Treatment of recurrent glioblastoma |
| Quantitative Effects | In the Phase Ia trial, disease stability was maintained for 312 days in 1 patient, and a partial response was confirmed during that period. |
| Usage history | 1 patient in the Phase Ia trial. Whether this is cumulative or as of a specific date is not disclosed. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To assess pharmacokinetics and efficacy based on the results of the Phase Ia trial, and to evaluate safety, tolerability, the recommended dose and antitumor effects.